Photo of Barrett J. Rollins,  MD, PhD

Barrett J. Rollins, MD, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-3896
Fax: (617) 632-5998


barrett_rollins@dfci.harvard.edu

Barrett J. Rollins, MD, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Linde Family Professor of Medicine, Medicine, Harvard Medical School
  • Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am interested in the molecular basis of cell migration in vivo. In particular, my lab focuses on how chemokines direct the movement of leukocytes and cancer cells to specific locations, and how chemokines contribute to tumor progression. My primary research model is genetically modified mice, and my group uses this model to investigate other aspects of chemokine physiology, such as their direct effects on innate and acquired immune responses and their effects on tumor biology. Much of our work involves examining the functions of the chemokine MCP-1, which plays a central role in polarizing T helper cell responses and is involved in diseases that have monocytic infiltrates such as atherosclerosis. However, we are also interested in Langerhans cell histiocytosis and the effects of chemokine receptor expression on patterns of organ involvement in this disease. My specific clinical interest is lung cancer, and when possible, our laboratory models address problems in this disease.

Publications

Powered by Harvard Catalyst
  • Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, Dubuc A, Brown L, Burns M, Cryan JB, Abedalthagafi M, Kang YJ, Schultz N, Reardon DA, Lee EQ, Rinne ML, Norden AD, Nayak L, Ruland S, Doherty LM, LaFrankie DC, Horvath M, Aizer AA, Russo A, Arvold ND, Claus EB, Al-Mefty O, Johnson MD, Golby AJ, Dunn IF, Chiocca EA, Trippa L, Santagata S, Folkerth RD, Kantoff P, Rollins BJ, Lindeman NI, Wen PY, Ligon AH, Beroukhim R, Alexander BM, Ligon KL. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. 2015. PubMed
  • Ribeiro KB, Degar B, Antoneli CB, Rollins B, Rodriguez-Galindo C. Ethnicity, race, and socioeconomic status influence incidence of Langerhans cell histiocytosis. Pediatr Blood Cancer 2015. PubMed
  • Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovée JV, Patel B, Badalian-Very G, van Hummelen P, Ducar M, Lin L, MacConaill LE, Egeler RM, Rollins BJ. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer 2015; 54:361-8. PubMed
  • MacConaill LE, Garcia E, Shivdasani P, Ducar M, Adusumilli R, Breneiser M, Byrne M, Chung L, Conneely J, Crosby L, Garraway LA, Gong X, Hahn WC, Hatton C, Kantoff PW, Kluk M, Kuo F, Jia Y, Joshi R, Longtine J, Manning A, Palescandolo E, Sharaf N, Sholl L, van Hummelen P, Wade J, Wollinson BM, Zepf D, Rollins BJ, Lindeman NI. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn 2014; 16:660-72. PubMed
  • Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, Jane-Valbuena J, Friedrich DC, Kryukov G, Carter SL, McKenna A, Sivachenko A, Rosenberg M, Kiezun A, Voet D, Lawrence M, Lichtenstein LT, Gentry JG, Huang FW, Fostel J, Farlow D, Barbie D, Gandhi L, Lander ES, Gray SW, Joffe S, Janne P, Garber J, MacConaill L, Lindeman N, Rollins B, Kantoff P, Fisher SA, Gabriel S, Getz G, Garraway LA. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 2014; 20:682-8. PubMed
  • Nelson DS, Quispel W, Badalian-Very G, van Halteren AG, van den Bos C, Bovée JV, Tian SY, Van Hummelen P, Ducar M, MacConaill LE, Egeler RM, Rollins BJ. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood 2014. PubMed
  • Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol 2014; 32:1317-23. PubMed
  • Bates SV, Lakshmanan A, Green AL, Terry J, Badalian-Very G, Rollins BJ, Fleck P, Aslam M, Degar BA. BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate. AJP Rep 2013; 3:63-6. PubMed
  • Badalian-Very G, Vergilio JA, Fleming M, Rollins BJ. Pathogenesis of Langerhans cell histiocytosis. Annu Rev Pathol 2013. PubMed
  • Liu Y, Quang P, Braggio E, Ngo H, Badalian-Very G, Flores L, Zhang Y, Sacco A, Maiso P, Azab AK, Azab F, Carrasco R, Rollins BJ, Roccaro AM, Ghobrial IM. Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma. PLoS ONE 2013; 8:e66982. PubMed
  • Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; 116:1919-23. PubMed
  • Collington SJ, Hallgren J, Pease JE, Jones TG, Rollins BJ, Westwick J, Austen KF, Williams TJ, Gurish MF, Weller CL. The role of the CCL2/CCR2 axis in mouse mast cell migration in vitro and in vivo. J Immunol 2010; 184:6114-23. PubMed
  • Rollins BJ. Where the confusion began: cloning the first chemokine receptors. J Immunol 2009; 183:2893-4. PubMed
  • Azab AK,Azab F,Blotta S,Pitsillides CM,Thompson B,Runnels JM,Roccaro AM,Ngo HT,Melhem MR,Sacco A,Jia X,Anderson KC,Lin CP,Rollins BJ,Ghobrial IM. Rho-A and Rac-1 GTPases play major and differential roles in SDF1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 2009; 114:619-29. PubMed
  • Roccaro AM,Sacco A,Thompson B,Leleu X,Azab AK,Azab F,Runnels J,Jia X,Ngo HT,Melhem MR,Lin CP,Ribatti D,Rollins BJ,Witzig TE,Anderson KC,Ghobrial IM. microRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009; 113:6669-80. PubMed
  • Roccaro AM,Sacco A,Chen C,Runnels J,Leleu X,Azab F,Azab AK,Jia X,Ngo HT,Melhem MR,Burwick N,Varticovski L,Novina CD,Rollins BJ,Anderson KC,Ghobrial IM. microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia. Blood 2008; 113:4391-402. PubMed
  • Azab AK,Runnels JM,Pitsillides C,Moreau AS,Azab F,Leleu X,Jia X,Wright R,Ospina B,Carlson AL,Alt C,Burwick N,Roccaro AM,Ngo HT,Farag M,Melhem MR,Sacco A,Munshi NC,Hideshima T,Rollins BJ,Anderson KC,Kung AL,Lin CP,Ghobrial IM. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113:4341-51. PubMed
  • Rodig SJ, Payne EG, Degar BA, Rollins B, Feldman AL, Jaffe ES, Androkites A, Silverman LB, Longtine JA, Kutok JL, Fleming MD, Aster JC. Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1. Am J Hematol 2007; 83:116-21. PubMed
  • Martin AP, Canasto-Chibuque C, Shang L, Rollins BJ, Lira SA. The chemokine decoy receptor M3 blocks CC chemokine ligand 2 and CXC chemokine ligand 13 function in vivo. J Immunol 2006; 177:7296-302. PubMed
  • Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur J Cancer 2006; 42:760-7. PubMed
  • Rollins BJ. Release the hounds! A chemokine elicits monocytes from bone marrow. Nat Immunol 2006; 7:230-2. PubMed
  • Kleine-Lowinski K, Rheinwald JG, Fichorova RN, Anderson DJ, Basile J, M. Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. Int J Cancer 2003; 107:407-15. PubMed
  • Degar BA, Rollins BJ. Langerhans cell histiocytosis: malignancy or inflammatory disorder doing a great job of imitating one? Dis Model Mech 2009; 2:436-9. PubMed
Hide